重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期宫颈癌的疗效及安全性分析

Analysis on the Efficacy and Safety of Recombinant Human p53 Adenovirus Injection Combined with Cisplatin and Paclitaxelin the Treatment of Advanced Cervical Cancer

目的探讨重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期宫颈癌的疗效及安全性。方法 80例晚期宫颈癌患者随机分为两组各40例,对照组给予顺铂与紫杉醇治疗,研究组在对照组基础上给予重组人p53腺病毒注射液治疗。比较两组的治疗效果、不良反应以及复发率、转移率、死亡率。结果研究组的治疗总有效率高于对照组,1年内病死率、复发率及转移率均低于对照组(P <0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期宫颈癌患者的疗效显著,安全性高,能够有效减少近期死亡、复发及转移。

Objective To explore the efficacy and safety of recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel in the treatment of advanced cervical cancer.Methods 80 patients with advanced cervical cancer were randomly divided into two groups,with 40 cases in each group.The control group was treated with cisplatin and paclitaxel,and the study group was treated with recombinant human p53 adenovirus injection on the basis of the control group.The therapeutic effect,adverse reactions,recurrence rate,metastasis rate and mortality rate were compared between two groups.Results The total effective rate of study group was higher than that of control group,and the mortality rate,recurrence rate and metastasis rate within 1 year were lower than those of control group(P<0.05).No significant difference was found in the incidence of adverse reactions between two groups(P>0.05).Conclusions Recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel in the treatment of advanced cervical cancer has significant efficacy and high safety,and can effectively reduce the recent death,recurrence and metastasis.